TIANSHAN BIO(SZ:300313) Mei Ri Jing Ji Xin Wen·2025-10-24 10:41Group 1 - The core point of the article is that *ST Tianshan announced the transfer of its 100% stake in Baluruk Livestock Co., Ltd. to Xiamen Yunjihuo Enterprise Network Technology Co., Ltd. for a nominal price of 1 RMB due to the poor long-term operating conditions of Baluruk and its insolvency [1] - The decision is part of the company's strategy to optimize its asset structure and focus on core business operations [1] - As of the first half of 2025, *ST Tianshan's revenue composition is 54.91% from the livestock industry and 45.09% from asset leasing [1] Group 2 - As of the report, *ST Tianshan has a market capitalization of 2.6 billion RMB [2] - The article highlights the booming secondary market for biopharmaceuticals in China, with 80 billion USD in overseas licensing deals this year [2] - There is a contrast noted between the hot secondary market and the cooling fundraising environment in the primary market for biopharmaceuticals [2]